Brief: ORIC Pharmaceuticals Q3 Net Income USD -34.566 Million
12/11/2024 21:05
Nov 12 (Reuters) - ORIC Pharmaceuticals Q3 basic EPS USD -0.49 vs. IBES estimate USD -0.48. * Q3 income from operations USD -38.318 million * Q3 operating expenses USD 38.318 million
Recent news on ORIC Pharmaceuticals
See all newsBrief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows